市场调查报告书
商品编码
1470553
避孕药市场:按产品、性别、方法和分布划分 - 2024-2030 年全球预测Contraceptive Market by Product (Devices, Drugs), Gender (Female Contraceptive, Male Contraceptive), Method, Distribution - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年避孕药具市场规模为484.3亿美元,预计2024年将达548.7亿美元,2030年将达1198.9亿美元,复合年增长率为13.82%。
避孕药,也称为避孕药具,是用于预防怀孕的方法或装置。这些产品和设备有多种作用,包括抑制卵子受精、防止受精卵植入子宫、调节荷尔蒙週期。避孕药具的可用性和选择使个人能够计划何时以及是否想要孩子,从而有助于改善妇女和家庭的健康状况。为提高性健康和避孕意识而进行的教育宣传活动和政府措施的增加导致人们更多地采用各种避孕方法。此外,新兴国家改善了获得卫生服务和计划生育的机会,并增加了避孕药具的使用。避孕方法的创新带来了更有效和用户友好的选择,也推动了市场的成长。然而,严格的法律规范可能会延迟产品的核准和推出。在一些地区,由于传统信仰和宗教限製而产生的阻力也会为市场带来挑战。然而,为了迎合具有环保意识的消费者,生物分解性和环保避孕产品的研究预计将成为市场成长的机会。此外,男性避孕用品新兴市场的开拓可能很快就会促进市场成长。
主要市场统计 | |
---|---|
基准年[2023] | 484.3亿美元 |
预测年份 [2024] | 548.7亿美元 |
预测年份 [2030] | 1198.9亿美元 |
复合年增长率(%) | 13.82% |
产品:易于使用和非侵入性导致避孕药物的更高趋势
保险套被广泛用作避孕屏障方法,既能避孕又能性行为感染(STI)。保险套通常由乳胶、聚氨酯或小羊皮製成,设计为一次性使用然后丢弃。隔膜是由硅胶或乳胶製成的浅圆顶形杯子,插入阴道腔以覆盖子宫颈并防止精子到达卵子。隔膜有多种尺寸,必须由医疗保健提供者安装,以确保正确使用和最大程度的保护。子宫内避孕器 (IUD),例如铜子宫内避孕器,会向子宫中释放少量铜,为精子创造一个有毒的环境。荷尔蒙子宫内避孕器会释放一种称为孕激素的激素,这种激素会使子宫颈黏液变稠并阻止精子到达卵子,这也会抑制排卵。皮下植入是一种插入上臂下方的小桿状装置,可持续释放阻止排卵的黄体素。避孕环,例如 NuvaRing,是一种插入阴道的柔性塑胶环,可释放雌激素和黄体素,以防止怀孕一个月。注射避孕药是每日避孕药的替代品,由医疗保健专业人员每三个月注射一次黄体素。口服避孕药 (OCP) 是最常见的避孕方法,有多种配方,可提供最佳的雌激素和黄体素效果。经皮吸收贴片是放置在皮肤上的荷尔蒙製剂,可将黄体素和雌激素释放到血液中,以有效控制节育。
性别:由于产品种类繁多,女性避孕药较受欢迎。
女性避孕药由多种旨在防止女性意外怀孕的产品组成。这些方法包括荷尔蒙避孕药,例如口服药丸、注射和贴片,以及荷尔蒙和铜基子宫内避孕器 (IUD)。包括隔膜、子宫颈帽和女性用保险套在内的避孕方法,以及紧急避孕药和输卵管结扎等永久性解决方案,也有助于提供可用的选择。最常见的男性避孕药具是保险套和输精管结扎(永久性外科手术)。然而,男性避孕领域取得了有希望的发展,包括旨在暂时抑制精子产生的荷尔蒙凝胶和注射。此外,研究正在扩展到非荷尔蒙方法,例如可逆精子引导抑制 (RISUG),它在输精管内充当物理屏障,以及在美国称为 Vasalgel 的类似方法。男性避孕药具的接受度和普及度受到文化态度、计划生育责任感和使用便利性的影响。
方式:越来越偏好在性行为过程中提供物理和化学屏障的屏障避孕方法
屏障避孕的原理是阻止精子到达卵子。这些包括男用和女性用保险套、隔膜、子宫颈帽和避孕海绵,它们描述了性行为过程中的物理或化学屏障。男用保险套是最广泛使用的屏障方法,因为它们容易取得且易于使用。它不仅可以有效预防怀孕,还可以降低各种性行为感染(STI)的风险。屏障方法通常是首选,因为它们不会对使用者的荷尔蒙产生系统性影响。它含有模仿雌激素和黄体酮天然激素的合成激素,可透过阻止排卵、增厚子宫颈黏液和改变子宫内膜来预防怀孕。有许多不同的类型,包括口服药、贴片、注射、避孕环和子宫内避孕器 (IUD)。荷尔蒙方法的有效性取决于严格遵守使用说明。其他好处包括规律的月经週期、减少月经疼痛以及降低某些生殖癌症的风险。无菌管是透过医疗程序实现的永久性避孕方法,例如女性输卵管结扎和男性输精管结扎或输精管闭塞。这种手术非常有效,失败率非常低,非常适合那些确定自己将来不想生孩子的人。女性节育手术通常比男性节育手术更复杂,风险也更大。在大多数情况下,这两种手术都是不可逆的,应该告知考虑节育手术的人,这种节育方法是永久性的。手术避孕是指最终导致不孕的手术,儘管该术语可能与上述不孕方法重迭,但它强调手术因素。对于女性来说,这包括传统的输卵管结扎术和最近的手术,例如腹腔镜在输卵管中放置闭合装置。对于男性来说,输精管切除术涉及切割和封闭切除术。这些永久性手术需要仔细考虑和知情同意。
分销:透过 24/7 线上药局加强产品分销
电子商务的兴起扩大了透过线上平台获得避孕药具的机会。这些数位市场使消费者能够轻鬆地大量购买避孕药具,从而获得当地可能无法获得的各种产品。诊所是避孕药具的主要分销管道,尤其是需要处方笺或咨询的产品,例如避孕药、子宫内避孕器和注射。这些医疗保健机构提供了从医疗保健专业人员那里获得有关最适合您个人需求的避孕方法的个人化建议和指导的机会。诊所可能隶属于大型医疗机构,也可能独立运营,通常专注于性健康和生殖健康。诊所经常与公共卫生部门合作,为贫困人群提供负担得起或免费的避孕药。同时,包括初级卫生中心、社区健康中心、州爱滋病控制协会等在内的政府网络正在针对低收入者和避孕手段有限的地区,往往以低成本或免费分发药物。这些网络在公共卫生工作中发挥重要作用,有助于让更多人更容易取得避孕药具。此外,能够随时取得产后和流产后避孕药具的医院药房对于避孕药具分销网络至关重要。设有专门生殖健康或计划生育科室的医院可能更需要此类产品。医院药房是患者的重要网路基地台,他们接受医疗保健专业人员的直接建议并在住院期间寻求保密。此外,独立药局和连锁药局提供有价值的服务,解决避孕药具取得的不同方面。独立药局专注于个人化照护和社区整合,而连锁药局提供有竞争力的价格和便利性。独立药局根据当地社区消费者的需求和偏好提供特殊化合物和各种选择。然而,连锁药局的产品阵容通常是按商店标准化的,这可能会限制寻求特定品牌或配方的消费者的选择。此外,避孕药等避孕药具的订阅服务正变得越来越受欢迎,并且可以透过自动化补充过程来提高用药依从性。
区域洞察
美洲的避孕药具市场是一个众所周知的成熟市场,大型製药公司的影响力很大。该地区的独特之处在于其广泛的避孕方法,包括避孕药、子宫内避孕器、植入和保险套。美国和加拿大的政府政策和非营利组织在提供可用的避孕方法方面发挥重要作用,特别是对于年轻人和低收入者。在旨在减少少女怀孕和增加避孕药具供应的公共卫生措施的推动下,拉丁美洲市场正在经历成长。欧洲、中东和非洲的避孕情况好坏参半。欧洲是一个成熟的市场,避孕普及很高,政府卫生系统可以低成本或免费提供各种避孕方法。人们强烈偏好长效可逆避孕方法 (LARC),例如子宫内避孕器 (IUD)。相较之下,文化和宗教因素影响中东地区避孕药具的使用,各国的避孕药具供应情况和社会接受度各不相同。非洲大陆是避孕普及最低的地区之一,国际援助和政府对妇女健康问题的日益关注正在增加对计划生育服务的需求。亚太地区呈现出多元化的避孕药具市场,并受到文化、社会和监管因素的显着影响。人口众多的国家的存在以及有关避孕药具使用的政府倡议和宣传宣传活动正在推动该地区的市场成长。
FPNV定位矩阵
FPNV定位矩阵对于评估避孕药市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对避孕市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该细分市场竞争特征的宝贵见解,包括在研究基准年观察到的累积、碎片化主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,以获得市场竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:包括新产品发布、开拓地区、最新发展和投资的详细资讯。
4. 竞争评估和情报:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。
5. 产品开发与创新:包括对未来技术、研发活动和突破性产品开发的智力见解。
1. 避孕药市场规模及预测是多少?
2. 在避孕市场的预测期内,我们应该考虑投资哪些产品和应用?
3. 避孕药具市场的技术趋势和法规结构是什么?
4.避孕药市场主要供应商的市场占有率是多少?
5. 进入避孕药具市场的适当形式和策略手段是什么?
[192 Pages Report] The Contraceptive Market size was estimated at USD 48.43 billion in 2023 and expected to reach USD 54.87 billion in 2024, at a CAGR 13.82% to reach USD 119.89 billion by 2030.
Contraceptives, also known as birth control, are methods or devices used to prevent pregnancy. These products or practices can work in various ways, such as inhibiting the fertilization of an egg, preventing the implantation of a fertilized egg in the uterus, or regulating hormonal cycles. The availability and choice of contraception provide individuals with the ability to plan if and when they want to have children, contributing to better health outcomes for women and families. Increased educational campaigns and government initiatives to raise awareness about sexual health and contraceptives have increased the adoption of various contraceptive methods. Further, enhanced access to healthcare services and family planning in emerging economies has increased the use of contraceptives. Innovations in contraceptive methods leading to more efficient and user-friendly options also bolstered the market growth. However, strict regulatory frameworks can delay product approvals and launches. Resistance in certain regions due to traditional beliefs and religious constraints may pose challenges for the market. Nevertheless, investigating biodegradable and eco-friendly contraceptive products to cater to environmentally conscious consumers is expected to provide an opportunistic way for market growth. Moreover, developments in male contraception methods may bolster the market growth shortly.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 48.43 billion |
Estimated Year [2024] | USD 54.87 billion |
Forecast Year [2030] | USD 119.89 billion |
CAGR (%) | 13.82% |
Product: High inclination toward contraceptive drugs due to their ease of use and non-invasiveness
Condoms are a widely used barrier method of contraception that provides both birth control and protection against sexually transmitted infections (STIs). Condoms are usually made of latex, polyurethane, or lambskin and are designed to be used once and disposed of after use. The diaphragm is a shallow, dome-shaped cup made of silicone or latex that is inserted into the vaginal cavity to cover the cervix and block sperm from reaching the ovum. Diaphragms are available in various sizes, and a healthcare provider must fit them to ensure proper use and maximum protection. Intrauterine devices (IUDs) such as Copper IUDs release a small amount of copper into the uterus, which creates a toxic environment for sperm. Hormonal IUDs release progestin, a hormone that thickens the cervical mucus to prevent sperm flow from reaching the egg and sometimes suppresses ovulation. Subdermal implants are small, rod-shaped devices inserted below the upper arm, releasing a continuous amount of progestin hormone to prevent ovulation. Vaginal rings, such as the NuvaRing, are flexible plastic rings that are inserted into the vagina and release both estrogen and progestin to offer month-long pregnancy protection. Injectable contraceptives are injections of progestin given by a healthcare professional every three months as an alternative to daily contraceptive pills. Oral contraceptive pills (OCPs) are the most common methods of contraception, available in various formulations of estrogen and progestin for optimal effectiveness. The transdermal patch is a hormonal contraceptive applied to the skin, releasing progestin and estrogen into the bloodstream to effectively control contraception.
Gender: Significant adoption of female contraceptives due to availability of a wide range of products
The female contraceptive comprises a diverse range of products aimed at enabling women to prevent unintended pregnancies. These methods include hormonal contraceptives such as oral contraceptive pills, injectables, and patches, as well as intrauterine devices (IUDs), both hormonal and copper-based. Contraceptive methods, including diaphragms, cervical caps, and female condoms, also contribute to the options available, alongside emergency contraceptive pills and permanent solutions such as tubal ligation. The most common male contraceptives include condoms and vasectomy, a permanent surgical procedure. However, there are promising developments in the field of male contraception, such as hormonal gels and injections that aim to inhibit sperm production temporarily. Furthermore, research into non-hormonal methods, including the reversible inhibition of sperm under guidance (RISUG) and a similar method in the U.S. known as Vasalgel, which acts as a physical barrier inside the vas deferens, is expanding. The acceptance and popularity of male contraceptives are influenced by cultural attitudes, perceived responsibility in family planning, and the convenience of use.
Method: Rising preference for barrier methods of contraception that provide a physical and chemical barrier during sexual activities
Barrier methods of contraception work by preventing the sperm from reaching the egg. These include male and female condoms, diaphragms, cervical caps, and contraceptive sponges, providing a physical or chemical barrier during sexual activities. Male condoms are the most widely used barrier method as they are readily available and easy to use. In addition to preventing pregnancy, these are effective in reducing the risk of various sexually transmitted infections (STIs). Barrier methods are often favored for their lack of systemic effects on the user's hormones. Hormonal contraceptives contain synthetic hormones that mimic estrogen and progesterone's natural hormones to prevent ovulation, thicken cervical mucus, or alter the uterine lining to prevent pregnancy. These types come in various forms, including oral pills, patches, injections, vaginal rings, and intrauterine devices (IUDs). The effectiveness of hormonal methods depends on strict adherence to their usage regimen. Additionally, these methods can offer benefits such as regulated menstrual cycles, reduced menstrual cramps, and a decreased risk of certain reproductive cancers. Sterilization is a permanent form of birth control achieved through medical procedures that close or block the fallopian tubes in females (tubal ligation) or the vas deferens in males (vasectomy). The procedures are highly effective with a very low rate of failure and are best suited for individuals who are sure they do not want children in the future. Female sterilization is usually more complex and carries greater risks than male sterilization, which is often a simpler outpatient procedure. Both procedures are irreversible in most cases, and individuals considering sterilization should be counseled on the permanent nature of this contraceptive method. Surgical contraception refers to procedures that ultimately lead to sterilization, and while the term may overlap with sterilization methods mentioned, it emphasizes the factor of surgery. For women, this includes both traditional tubal ligation and more recent procedures, such as the laparoscopic placement of occlusive devices on the fallopian tubes. For men, vasectomy involves the cutting and sealing of the vas deferens. These permanent procedures require careful consideration and informed consent, as reversal attempts may not be successful and are often costly.
Distribution Channel: Enhanced product distribution through online pharmacies due to their 24/7 services
The rise of eCommerce has expanded the availability of contraceptives through online platforms. These digital marketplaces allow consumers to purchase contraceptives discretely and conveniently, providing access to various products that may not be available in their immediate geographical area. Clinics serve as a primary distribution channel for contraceptives, particularly for forms requiring prescription or medical consultation, such as birth control pills, IUDs, and injectables. These healthcare facilities provide an opportunity for individuals to receive personalized advice and guidance from health professionals about the most appropriate contraceptive method for their needs. Clinics may be affiliated with larger healthcare institutions or operate independently, often focusing on sexual and reproductive health. They often work in conjunction with public health initiatives to provide affordable or free contraceptives to underprivileged populations. On the other hand, Government networks, including Primary Health Centers, Community Health Centers, State AIDS Control Societies, and many others, distribute contraceptives often at reduced or no cost, targeting lower-income brackets and regions with limited access to healthcare. These networks have a crucial role in public health initiatives and are instrumental in making contraceptives accessible to a broader audience. Further, hospital pharmacies are integral to the distribution network for contraceptives as they provide immediate access to postpartum and post-abortion contraceptives. Hospitals with specialized reproductive health or family planning divisions may need such products more. Hospital pharmacies are an important access point for patients seeking confidentiality and direct recommendations from healthcare providers during their hospital stay. Furthermore, independent and chain pharmacies offer valuable services catering to different aspects of contraceptive access. Independents focus on personalized care and community integration, while chains excel in price competitiveness and convenience. Independent pharmacies offer specialized compounds and a range of options tailored to consumer feedback and preferences in their local community. However, chain pharmacy product range is often standardized across locations, potentially limiting options for consumers seeking specific brands or formulations. Moreover, subscription services for contraceptives, such as birth control pills, have become increasingly popular and can improve adherence by automating the refill process.
Regional Insights
The contraceptive market in the Americas presents a mature landscape with high awareness levels and a strong presence of major pharmaceutical companies. The region is characterized by a wide range of contraceptive methods including birth control pills, IUDs, implants, and condoms. Government policies and non-profit organizations in the United States and Canada play a crucial role in providing accessible contraception, particularly to younger and lower-income populations. The Latin American market is experiencing growth, propelled by public health initiatives aimed at reducing teenage pregnancies and increasing the availability of contraceptives. The EMEA region presents a varying landscape for contraceptives. Europe has a well-established market with high contraceptive prevalence rates, backed by governmental healthcare systems that offer various contraceptive methods at low or no cost. There is a strong tendency toward long-acting reversible contraceptives (LARCs) such as IUDs. The Middle East, contrastingly, has cultural and religious factors that influence contraceptive use, with varying degrees of accessibility and societal acceptance across different countries. The African continent shows the lowest contraceptive prevalence rate and is experiencing a rise in need for family planning services, driven by international aid, and increasing government focus on women's health issues. The Asia-Pacific region showcases a diverse contraceptive market, heavily influenced by cultural, social, and regulatory factors. The presence of high-population countries coupled with government initiatives and awareness campaigns for the use of contraceptives has propelled the market growth in the region.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Contraceptive Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Contraceptive Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Contraceptive Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Acme Generics Pvt. Ltd., Afaxys, Inc., Agile Therapeutics, Inc., Amneal Pharmaceuticals LLC, ASKA Pharmaceutical Co., Ltd., Aurobindo Pharma Limited, Bayer AG, Church & Dwight Co., Inc., HLL Lifecare Limited, Insud Pharma, S.L., Johnson & Johnson Services, Inc., Lupin Limited, Mayne Pharma Group Limited, Merck & Co., Inc., Mithra Pharmaceuticals S.A., Okamoto Industries, Inc., Organon & Co., Perrigo Company plc, Pfizer Inc., Piramal Pharma Ltd., Reckitt Benckiser Group plc, RITEX GMBH, Sanofi S.A., Say It With A Condom, LLC., Syzygy Healthcare Solutions LLC, Teva Pharmaceutical Industries Ltd., TherapeuticsMD, Inc., TTK Healthcare Limited, Veru Inc., and Viatris Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Contraceptive Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Contraceptive Market?
3. What are the technology trends and regulatory frameworks in the Contraceptive Market?
4. What is the market share of the leading vendors in the Contraceptive Market?
5. Which modes and strategic moves are suitable for entering the Contraceptive Market?